Literature DB >> 1695682

Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.

M Turconi1, M Nicola, M G Quintero, L Maiocchi, R Micheletti, E Giraldo, A Donetti.   

Abstract

A series of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid esters and amides containing a basic azacyclo- or azabicycloalkyl moiety has been synthesized and evaluated for 5-HT3 antagonistic activity in a radioligand binding assay ([3H]ICS 205930) and in the 5-HT-induced von Bezold-Jarisch reflex in the rat. It was found that endo-substituted azabicycloalkyl derivatives (e.g. 7a, 12a, 12b) were much more active than the corresponding exo analogues (e.g. 7b, 12h, 12i) or azacycloalkyl compounds. Amidic derivatives 12a, 12b, 12c, 12e, 13b, and 13c proved to be about 10 times more active than the corresponding ester derivatives 7a, 11a, 7c, 7d, 8a, and 8b. In particular, compound 12a (DA 6215) showed a Ki = 3.8 nM in the binding test and an ED50 = 1 nM/kg iv in the von Bezold-Jarisch reflex assay, an activity comparable to that of the reference compound 2 (ICS 205930, Ki = 2 nM, ED50 = 2.1 nM/kg). IR spectroscopy studies in the solid state and in CHCl3 solution revealed the existence of an intramolecular hydrogen bond in 13b, taken as a model compound for this class of substances. A molecular modeling study showed that 12a, in its internal hydrogen-bound conformation, well matches a recently proposed pharmacophoric model for 5-HT3 antagonist activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695682     DOI: 10.1021/jm00170a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4 receptor positively coupled to adenylate cyclase in brain.

Authors:  A Dumuis; M Sebben; E Monferini; M Nicola; M Turconi; H Ladinsky; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-03       Impact factor: 3.000

2.  Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors.

Authors:  C A Rizzi; A Sagrada; A Schiavone; P Schiantarelli; R Cesana; G B Schiavi; H Ladinsky; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

3.  Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285.

Authors:  A Dumuis; H Gozlan; M Sebben; H Ansanay; C A Rizzi; M Turconi; E Monferini; E Giraldo; P Schiantarelli; H Ladinsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

4.  The 5-HT4 receptor subtype inhibits K+ current in colliculi neurones via activation of a cyclic AMP-dependent protein kinase.

Authors:  L Fagni; A Dumuis; M Sebben; J Bockaert
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

5.  Effects of DAU 6215, a novel 5-hydroxytryptamine3 (5-HT3) antagonist on electrophysiological properties of the rat hippocampus.

Authors:  M B Passani; A M Pugliese; M Azzurrini; R Corradetti
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

6.  Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.

Authors:  A Sagrada; M Turconi; P Bonali; P Schiantarelli; R Micheletti; E Montagna; M Nicola; D R Algate; E M Rimoldi; A Donetti
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.